Novartis raises peak sales targets for key drugs, projects 5% growth through 2031
By: IPP Bureau
Last updated : November 20, 2026 10:56 am
Drugmaker boosts sales potential of Kesimpta, Scemblix and Leqvio as it banks on a robust pipeline of 30-plus high-value assets to sustain long-term growth
Novartis has raised its peak sales forecasts for three major drugs and reaffirmed its ambition to deliver sustained growth through 2031, signalling confidence in its expanding portfolio and late-stage development pipeline.
The Swiss pharmaceutical giant has rolled forward its mid-term guidance for 2026-2031, targeting a compound annual growth rate (CAGR) of at least 5% in net sales at constant currencies. It also expects its core operating income margin to return to more than 40% by 2029.
The upgraded outlook, set to be presented at the company's Meet Novartis Management event in London, is underpinned by stronger growth prospects for established brands and a pipeline of potential new launches.
Novartis has significantly increased peak sales expectations for three key medicines:
Kesimpta: Raised from $6 billion to $8 billion.
Scemblix: Raised from $4 billion to $5 billion.
Leqvio: Raised from $4 billion to $5 billion.
The revisions follow a recent upgrade in the peak sales forecast for Rhapsido (remibrutinib) to $8 billion across chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and relapsing multiple sclerosis (RMS). The drug also carries additional multi-billion-dollar sales potential across other indications.
With these upgrades, Novartis now counts nine de-risked, in-market assets with peak sales potential ranging from $3 billion to $10 billion. The portfolio includes Kisqali, Rhapsido, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, the Zolgensma Group (Zolgensma and Itvisma), and Fabhalta.
Pipeline bets to power next growth phase
Beyond its established medicines, Novartis is banking on a deep development pipeline to sustain growth well into the next decade.
The company expects more than 35 potentially submission-enabling readouts through 2031. Its pipeline comprises over 30 potential high-value assets across four core therapeutic areas and three advanced technology platforms.
Of these, more than 20 are in registration, Phase III or Phase II development, while over 10 are currently in or entering Phase I. Ten late-stage assets already carry multi-billion-dollar peak sales potential, strengthening the company's long-term growth prospects.
"As a pure-play innovative medicines company, Novartis has a strong track record of sales growth and core margin expansion, and in 2026 we expect to grow through the largest loss-of-exclusivity impact in our history,” said Vas Narasimhan, CEO of Novartis.
“The strength of our in-market portfolio is reflected in higher peak sales guidance for Rhapsido, Kesimpta, Scemblix and Leqvio, which together with our other priority brands underpin our expectation of a +5% cc¹ sales CAGR through 2031. Alongside our late-stage programs advancing through Phase III, our full Phase I and II pipeline gives us further confidence that we can sustain mid-single-digit growth over the longer term.”
AI takes centre stage in strategy update
The London event will also offer investors and analysts a broader look at Novartis' strategy, operational priorities and growth plans.
Narasimhan is scheduled to deliver a strategy and performance update, including details of how the company is scaling artificial intelligence across research, development, manufacturing and commercial operations.
Investors and analysts will also have the opportunity to engage directly with senior leaders across the company's therapeutic areas through an open question-and-answer session.